Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Revotar reports positive results with small molecule selectin antagonist
September 1st, 2003
Encysive Pharmaceuticals (ENCY) announced its majority-owned German affiliate, Revotar Biopharmaceuticals, AG, reported positive results with bimosiamose in a 12-patient, double-blind, cross-over, allergen challenge study in mild asthmatics. The results demonstrated for the first time that a small molecule selectin antagonist can decrease Late Asthmatic Response (LAR), a standard measure of asthma, in patients following allergen challenge. The study with bimosiamose achieved its primary endpoint of LAR decline vs. maximum FEV1 baseline values (p=0.05, Wilcoxon Signed Rank Test). This endpoint is recommended by the American Thoracic Society for asthma...
Source: Health & Medicine Week (2003-09-01)
|
